Atosiban in the management of preterm labour

Research output: Contribution to journalLiterature review

3 Downloads (Pure)

Abstract

The purpose of this review was to look at the evidence available for the use of atosiban as a tocolytic in cases of threatened preterm labour. A Royal College of Obstetricians and Gynaecologists Green Top Guideline concluded that there was no clear evidence to show a benefit to tocolysis in reducing perinatal and neonatal morbidity and mortality. Using a systematic literature search, we summarise the evidence available on the use of atosiban for the prevention of preterm birth and compare it with other commonly used tocolytic agents in terms of efficacy, patient preference and drug safety. We conclude that although atosiban appears to be the tocolytic of choice, a clear benefit of using tocolysis in all cases of threatened preterm labour remains to be justified and clinical management should be tailored according to individual needs.
Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalClinical Medicine Insights: Women's Health
Volume4
DOIs
Publication statusPublished - 27 Feb 2011

Fingerprint

Tocolytic Agents
Premature Obstetric Labor
Tocolysis
Patient Preference
Premature Birth
Infant Mortality
Guidelines
Morbidity
Safety
Pharmaceutical Preparations
atosiban

Keywords

  • atosiban
  • preterm birth
  • tocolysis
  • oxytocin inhibitor

Cite this

Atosiban in the management of preterm labour. / Fullerton, Gail M; Black, Mairead; Shetty, Ashalatha; Bhattacharya, Sohinee.

In: Clinical Medicine Insights: Women's Health, Vol. 4, 27.02.2011, p. 9-16.

Research output: Contribution to journalLiterature review

@article{dd17a769349b4187a8a341d4c20107d5,
title = "Atosiban in the management of preterm labour",
abstract = "The purpose of this review was to look at the evidence available for the use of atosiban as a tocolytic in cases of threatened preterm labour. A Royal College of Obstetricians and Gynaecologists Green Top Guideline concluded that there was no clear evidence to show a benefit to tocolysis in reducing perinatal and neonatal morbidity and mortality. Using a systematic literature search, we summarise the evidence available on the use of atosiban for the prevention of preterm birth and compare it with other commonly used tocolytic agents in terms of efficacy, patient preference and drug safety. We conclude that although atosiban appears to be the tocolytic of choice, a clear benefit of using tocolysis in all cases of threatened preterm labour remains to be justified and clinical management should be tailored according to individual needs.",
keywords = "atosiban, preterm birth, tocolysis, oxytocin inhibitor",
author = "Fullerton, {Gail M} and Mairead Black and Ashalatha Shetty and Sohinee Bhattacharya",
year = "2011",
month = "2",
day = "27",
doi = "10.4137/CMWH.S5125",
language = "English",
volume = "4",
pages = "9--16",
journal = "Clinical Medicine Insights: Women's Health",
issn = "1178-2196",

}

TY - JOUR

T1 - Atosiban in the management of preterm labour

AU - Fullerton, Gail M

AU - Black, Mairead

AU - Shetty, Ashalatha

AU - Bhattacharya, Sohinee

PY - 2011/2/27

Y1 - 2011/2/27

N2 - The purpose of this review was to look at the evidence available for the use of atosiban as a tocolytic in cases of threatened preterm labour. A Royal College of Obstetricians and Gynaecologists Green Top Guideline concluded that there was no clear evidence to show a benefit to tocolysis in reducing perinatal and neonatal morbidity and mortality. Using a systematic literature search, we summarise the evidence available on the use of atosiban for the prevention of preterm birth and compare it with other commonly used tocolytic agents in terms of efficacy, patient preference and drug safety. We conclude that although atosiban appears to be the tocolytic of choice, a clear benefit of using tocolysis in all cases of threatened preterm labour remains to be justified and clinical management should be tailored according to individual needs.

AB - The purpose of this review was to look at the evidence available for the use of atosiban as a tocolytic in cases of threatened preterm labour. A Royal College of Obstetricians and Gynaecologists Green Top Guideline concluded that there was no clear evidence to show a benefit to tocolysis in reducing perinatal and neonatal morbidity and mortality. Using a systematic literature search, we summarise the evidence available on the use of atosiban for the prevention of preterm birth and compare it with other commonly used tocolytic agents in terms of efficacy, patient preference and drug safety. We conclude that although atosiban appears to be the tocolytic of choice, a clear benefit of using tocolysis in all cases of threatened preterm labour remains to be justified and clinical management should be tailored according to individual needs.

KW - atosiban

KW - preterm birth

KW - tocolysis

KW - oxytocin inhibitor

U2 - 10.4137/CMWH.S5125

DO - 10.4137/CMWH.S5125

M3 - Literature review

VL - 4

SP - 9

EP - 16

JO - Clinical Medicine Insights: Women's Health

JF - Clinical Medicine Insights: Women's Health

SN - 1178-2196

ER -